期刊
NATURE COMMUNICATIONS
卷 8, 期 -, 页码 -出版社
NATURE PUBLISHING GROUP
DOI: 10.1038/s41467-017-00924-7
关键词
-
资金
- Muscular Dystrophy Association [MDA295203]
- National Institutes of Health NICHD [5U54HD071601]
- National Institutes of Health NIAMS T32 Genetics and Genomics of Muscle Post-doctoral Training Grant [T32AR056993]
- Parent Project Muscular Dystrophy
- Muscular Dystrophy Association Development Grant [MDA480160]
- Duchenne Parent Project-Netherlands Development Grant
- Clark Charitable Foundation
- Foundation to Eradicate Duchenne
- French Muscular Dystrophy Association [AFM17611]
- Sarepta Therapeutics
- German Research Foundation [DFGC1218/1]
Exon skipping is a promising therapeutic strategy for Duchenne muscular dystrophy (DMD), employing morpholino antisense oligonucleotides (PMO-AO) to exclude disruptive exons from the mutant DMD transcript and elicit production of truncated dystrophin protein. Clinical trials for PMO show variable and sporadic dystrophin rescue. Here, we show that robust PMO uptake and efficient production of dystrophin following PMO administration coincide with areas of myofiber regeneration and inflammation. PMO localization is sustained in inflammatory foci where it enters macrophages, actively differentiating myoblasts and newly forming myotubes. We conclude that efficient PMO delivery into muscle requires two concomitant events: first, accumulation and retention of PMO within inflammatory foci associated with dystrophic lesions, and second, fusion of PMO-loaded myoblasts into repairing myofibers. Identification of these factors accounts for the variability in clinical trials and suggests strategies to improve this therapeutic approach to DMD.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据